AbbVie has entered into a $1 billion licensing agreement with IGI Therapeutics SA, for IGI's lead investigational drug for ...

AbbVie partners with IGI Therapeutics for ISB 2001, a potential cancer and autoimmune therapy. Read more here.

Get the latest Outlook Therapeutics, Inc. (OTLK) stock news and headlines to help you in your trading and investing decisions.

Eli Lilly is to buy the private biotech Disarm Therapeutics, which is working on a new class of disease-modifying drugs for neurological diseases, in a deal worth up to $1.36 billion.

House Oversight Committee passes BIOSECURE Act, which would restrict US companies from contracting with Chinese biotechs, including WuXi AppTec, MGI, and BGI.